Introduction {#Sec1}
============

[l-]{.smallcaps}Methotrexate ([l-]{.smallcaps}MTX, amethopterin, (2S)-2-\[\[4-\[(2,4-diaminopteridin-6-yl)methyl-methylamino\]benzoyl\]amino\]pentanedioic acid) (Fig. [1](#Fig1){ref-type="fig"}) is an antimetabolite of folic acid that is widely used for the treatment of several cancers, including childhood leukemia, head and neck cancer, and micrometastases of osteosarcoma. More recently, it is also being used at low dose for the treatment of rheumatoid arthritis, psoriasis, and steroid-dependent asthma \[[@CR1]--[@CR3]\]. [l-]{.smallcaps}MTX acts by inhibiting the enzyme dihydrofolate reductase (i.e., disruption of folate biosynthesis) due to its greater affinity for the enzyme than the closely related folic acid. This means that in the presence of [l-]{.smallcaps}MTX, key reactions in cell division are shut down \[[@CR4]\]. The [d]{.smallcaps}-enantiomer ([d]{.smallcaps}-MTX) is subject to significantly different pharmacokinetics; it has a similar inhibitory effect on dihydrofolate reductase, but its antitumor effect is reduced \[[@CR1], [@CR5]\]. For that reason, [d]{.smallcaps}-MTX has to be considered as a chiral impurity of [l-]{.smallcaps}MTX; it can originate from the synthesis of [l-]{.smallcaps}MTX or from racemization during the shelf life of the pharmaceutical product under improper storage conditions \[[@CR6]\]. Regulatory requirements regarding the purity of chiral drugs have generally become stricter in recent years; therefore, the development of analytical methodologies to test for enantiomeric impurities in pharmaceutical formulations is of great importance. Fig. 1Structure and p*K*~a~ of [l]{.smallcaps}-methotrexate

Among the analytical techniques currently used for the purity control of pharmaceuticals, electrokinetic chromatography (EKC), a mode of capillary electrophoresis (CE), was shown to be a powerful tool in the field of chiral separations \[[@CR7]--[@CR17]\]. With UV absorption detection, which is still used most often in CE, the concentration sensitivity is limited by the optical path length of the capillary. For compounds with a chromophoric group, concentration limits in the micromolar range may be achieved in the most favorable cases \[[@CR18]\]. Such detection limits may not be sufficiently low for biomedical samples or if low concentrations of enantiomeric impurities have to be detected. Therefore, we set out to investigate whether luminescence methods (preferably without chemical derivatization) can provide a suitable alternative.

Next to fluorescence detection, which is well established in CE, room temperature phosphorescence (RTP) in liquid deoxygenated solutions was shown to be an attractive luminescence spectroscopic method for detection in CE \[[@CR19]--[@CR27]\]. Apart from direct phosphorescence, where the analyte is excited by light of an appropriate wavelength and phosphoresces itself, several indirect phosphorescence modes can be distinguished. In one sensitized mode, the analyte is excited and transfers its excitation energy to a more strongly phosphorescent acceptor added to the background electrolyte (BGE), after which the emission of the latter is observed. That approach was used in a previous paper on the enantioseparation and phosphorescence detection of bupropion \[[@CR27]\]. Alternatively, one can excite a donor reagent with excellent absorption properties, which then transfers its electronic energy to the analyte of which the emission is detected \[[@CR28]\]. Finally, in the quenched mode, a phosphorescent reagent is excited and its phosphorescence quantum yield is reduced by a biomolecular quenching process with an analyte molecule, which leads to negative peaks in the electropherogram \[[@CR20], [@CR21], [@CR29], [@CR30]\]. Importantly, in the latter mode, also non-phosphorescent analytes can be detected, which is the case in this study. It should be noted that quenched phosphorescence is different from the indirect UV absorption mode, which is based on electrophoretic displacement of the BGE by the analytes.

Examination of the literature reveals that chiral discrimination of MTX has been achieved by means of different analytical techniques such as amperometric biosensors \[[@CR31]\], voltammetric methods \[[@CR32]\], potentiometric membrane electrodes \[[@CR1]\], TLC \[[@CR33]\], HPLC \[[@CR6], [@CR34], [@CR35]\], and CE \[[@CR5], [@CR36]--[@CR39]\]. In the case of CE, the chiral separation of MTX and other compounds was carried out to evaluate vancomycin \[[@CR36]\], [d]{.smallcaps}-(+)-tubocurarine \[[@CR37]\], and cyclosophoraoses \[[@CR39]\] as chiral selector. Moreover, Kuo et al. \[[@CR38]\] developed a method for the enantiomeric analysis of MTX in pharmaceuticals using 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) as chiral selector. However, this method was only applied to verify the content of [l-]{.smallcaps}MTX in tablets and injection formulations, but not for purity control. On the other hand, Gotti et al. \[[@CR5]\] carried out the determination of achiral and chiral impurities of [l-]{.smallcaps}MTX in pharmaceuticals using a micellar EKC system with β-CD.

In this work, we explore the applicability of phosphorescence as detection mode for the chiral separation of MTX by EKC. First, the direct and indirect phosphorescence properties of MTX were investigated in batch experiments. The quenched phosphorescence mode was found to be appropriate for the detection of MTX in combination with its chiral separation. In addition, the influence of different experimental conditions on the enantiomeric separation was also studied. Finally, the method developed in this work was applied to the enantiomeric purity control of [l-]{.smallcaps}MTX in a pharmaceutical formulation, to a short-term stability study, and to the determination of [l-]{.smallcaps}MTX in a cell culture extract.

Material and methods {#Sec2}
====================

Reagents and samples {#Sec3}
--------------------

All reagents employed were of analytical quality. Sodium phosphate monobasic, methanol, and β-CD were purchased from Sigma (St. Louis, MO, USA). Sodium hydroxide was obtained from Fluka (Buchs, Switzerland). (±)-Camphorquinone (CQ) and HP-β-CD were from Aldrich (Steinheim, Germany). 1-Bromo-4-naphthalenesulfonic acid (BrNS) was synthesized in-house \[[@CR40]\]. Water used for preparing the solutions was purified through a Milli-Q system from Millipore (Bedford, MA, USA). [l-]{.smallcaps}MTX was obtained from Aldrich (Steinheim, Germany), and [d]{.smallcaps}-MTX was kindly provided by Dr. R. Gotti (University of Bologna, Italy). The pharmaceutical formulation analyzed (Emthexate PF, 100 mg/mL; Pharmachemie BV, Haarlem, the Netherlands) and the [l-]{.smallcaps}MTX containing cell culture extract were kindly provided by Dr. G. Jansen and I. Kathman (VU Medical Center, Amsterdam, the Netherlands).

Instrumentation {#Sec4}
---------------

A Cary Eclipse Luminescence Spectrometer (Varian, Melbourne, Australia) equipped with a pulsed Xe lamp was used for the batch experiments. The samples were deoxygenated using a stable nitrogen flow in a long-necked cuvette with a stopper and narrow vent (Hellma, Müllheim, Germany). The temperature was kept at 20 °C using the single-cell Peltier Cooler of the spectrometer. The phosphorescent reagents BrNS and CQ were excited at 294 or 470 nm, respectively. Excitation and emission bandwidths were set to 10 nm and the PMT voltage was 600 V. To avoid detecting interfering scatter and fluorescence, a delay time of 0.1 ms and a gate time of 5.0 ms were used. For the lifetime measurements, the initial delay time and the gating time were set at 0.05 ms. Decay curves were fitted in OriginPro 8.

EKC separations were carried out using a CE system (200 series) from Prince Technologies (Emmen, the Netherlands) with an uncoated fused silica capillary of 75-μm i.d. (375-μm o.d.) and an effective length of 70 cm (total length 120 cm) from Polymicro (Phoenix, AZ, USA). The measurements were made at room temperature, the voltage applied was 30 kV, and the samples were injected by pressure (50 mbar for 0.08 min). Since deoxygenation is required to observe RTP, a modified vial was used to purge the buffer solution continuously with nitrogen \[[@CR19]\]. The nitrogen flow rate was kept constant with a flow regulator. Before first use, a new capillary was rinsed with 1 M NaOH for 30 min, followed by 2 min with Milli-Q water, 60 min with the buffer, and 5 min with the BGE (purged with nitrogen for at least 10 min before the start of the analysis and during the separation to remove oxygen). Between runs, the capillary was rinsed with BGE for 2 min.

An LS-40 Luminescence LC detector (Perkin-Elmer, Beaconsfield, U.K.), adapted for CE \[[@CR30]\], was used as phosphorescence detection system. The delay time was 0.08 ms and the gating time 3.00 ms. Lamp excitation was performed at 294 nm and emission was collected by means of the total emission mirror and the 390-nm cutoff filter provided with the instrument.

Analytical procedure {#Sec5}
--------------------

Running buffers were prepared by dissolving the appropriate amount of sodium phosphate in Milli-Q water, adjusting the pH with 1 M NaOH before completing the volume to get the desired buffer concentration (25 mM). BGEs were prepared by dissolving the appropriate amount of cyclodextrins in the buffer solution. Stock solutions of 0.025 M BrNS and 0.1 M (±)-CQ were prepared in water and MeOH, respectively, and stored at 5 °C. Stock solutions of [l]{.smallcaps}**[-]{.smallcaps}** or [d]{.smallcaps}-MTX were prepared by dissolving the appropriate amount of each enantiomer in 0.1 M NaOH up to a final concentration of 10^−3^ M (stored at −20 °C). Aliquots were diluted in water to get solutions with the desired concentrations (using an L/D ratio of 2:1 for easy distinction of the two peaks).

Human CEM leukemia cells (5 × 10^6^ CEM-WT) were centrifuged (528×*g* for 5 min at room temperature), and the pellet was washed with 20 mL (4 °C) Hanks balanced salt solution (HBSS) buffer containing 20 mM HEPES, 140 mM NaCl, 6 mM KCl, 2 mM MgCl~2~, and 6 mM glucose, pH 7.4, set with NaOH. After centrifugation (528×*g* for 5 min at 4 °C), the pellet was resuspended in 1 mL HBSS (4 °C) followed by centrifugation (15,294×*g* for 5 min at 4 °C). The pellet obtained was resuspended in 150 μL HBSS (4 °C) and spiked with 1 μM MTX and 40 μL ice-cold 40% trichloroacetic acid. After 20 min, the cell suspension was shaken and centrifuged at 15,294×*g* for 5 min at 4 °C, and the supernatant was separated and suspended in alamine/freon. Finally, the aqueous layer was separated by centrifugation (15,294×*g*, 5 min, 4 °C) and stored at −20 °C.

All BGEs, standards, and samples were filtered through 0.2-μm syringe filters (Whatman, Dassel, Germany) before their use in the CE system.

Results and discussion {#Sec6}
======================

Batch experiments {#Sec7}
-----------------

According to the literature, the enantiomeric separation of MTX by EKC can be achieved using HP-β-CD as chiral selector in phosphate buffer at pH 7.0 \[[@CR38]\]. Keeping in mind that the objective of this work was to investigate the feasibility of phosphorescence detection in CE as an alternative to UV detection, we employed these preliminary conditions to study the direct and indirect phosphorescence of MTX in batch.

In order to find optimum excitation conditions, first of all, the absorption and fluorescence spectra were recorded. In UV--Vis absorption, four maxima can be discerned, i.e., at 220, 259, 303, and 373 nm. Under the experimental conditions, MTX was found to be weakly fluorescent, too weak to be of interest from an analytical detection point of view. Interestingly, in fluorescence instead of a single emission spectrum---as generally expected---two weak emission bands were found, i.e., at 356 and 465 nm (not shown). This is not due to the presence of two species, but is attributed to the fact that MTX is composed of two separate chromophoric moieties, connected by an aliphatic --C--N-- group. The corresponding excitation spectra are distinctly different: The maxima at 220 and 303 nm are associated with the 365-nm band; those at 259 and 373 nm with the 456-nm band. Thus, there are two suitable excitation wavelengths for MTX: 303 and 373 nm, corresponding presumably with the benzoyl and the pteridin unit.

Also, two phosphorescence emission signals could be expected, but under deoxygenated conditions, no direct phosphorescence was observed at either excitation wavelength (303 and 373 nm). Therefore, indirect phosphorescence in sensitized and quenched mode was explored. For this purpose, the phosphorophores BrNS and CQ were tested; both compounds have been used extensively in earlier studies \[[@CR19], [@CR21]--[@CR23], [@CR26], [@CR28], [@CR40], [@CR41]\]. In the sensitized phosphorescence mode, MTX, is excited and transfers its excitation energy to BrNS or CQ, of which the phosphorescence is then observed. When BrNS was used as acceptor, MTX was only excited at 373 nm since 303 nm is too close to the maximum excitation wavelength of BrNS (294 nm) and would thus result in a high background from direct excited acceptor. In the case of BrNS, sensitized phosphorescence was not observed. For CQ, the energy transfer from MTX (excited at 303 or 373 nm) resulted in only a small increase in the CQ phosphorescence signal (data not shown). Thus, we concluded that also sensitized phosphorescence is not a promising option for MTX detection. Presumably, for both chromophoric moieties, the triplet state energies are too low for efficient transfer to BrNS or CQ.

In the dynamically quenched mode, BrNS or CQ are excited (at 294 or 470 nm, respectively), and their phosphorescence intensity is monitored. If MTX has a lower triplet state energy, the transfer of excitation energy from the phosphorophore to MTX can take place, which diminishes the observed phosphorescence intensity from *I*~0~ to *I* according to the Stern--Volmer equation: $$\documentclass[12pt]{minimal}
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Figure [2](#Fig2){ref-type="fig"} shows the phosphorescence emission spectra of BrNS and CQ, recorded in batch in the presence of HP-β-CD, with and without 10^−5^ M **[l-]{.smallcaps}**MTX. In the absence of quencher, the phosphorescence intensity of BrNS was about 50 times higher than that of CQ. For both phosphorophores, the presence of **[l-]{.smallcaps}**MTX resulted in a decrease of the signal: *I*~0~/*I* = 15.3 for BrNS and 1.5 for CQ. Lifetime measurements showed that in both cases, we are indeed dealing with dynamic quenching: For instance, for BrNS, the phosphorescence lifetime decreased from 2.05 to 0.150 ms in the presence of MTX. This 14-fold decrease is very close to the observed change in intensity. The rate constant of quenching *k*~q~ was calculated from Eq. [1](#Equ1){ref-type=""} as 7 × 10^8^ M^−1^ s^−1^, close to the typical rate constant of collisional quenching (1--5 × 10^9^ M^−1^ s^−1^). Fig. 2Phosphorescence emission spectra of 10^−5^ M BrNS (**a**) and 2 mM (±)-CQ (**b**) with and without quenching by [l]{.smallcaps}-MTX (10^−5^ M) in 25 mM phosphate buffer (pH 7.0) with 3 mg/mL HP-β-CD. Batch measurements: spectrometer settings---delay time, 0.1 ms; gating time, 5.0 ms; *λ*~exc~ = 294 nm for BrNS and 470 nm for (±)-CQ; excitation and emission band widths, 10 nm. All samples were purged with nitrogen to remove oxygen

In dynamically quenched phosphorescence detection for CE, a high background signal (with relatively low noise) and a long triplet lifetime *τ*~0~ are preferred for maximum sensitivity. Therefore, the quenched mode with BrNS was selected for further experiments.

CE phosphorescence {#Sec8}
------------------

For the optimization of the CE separation, we started out from the experimental conditions described by Kuo et al. \[[@CR38]\] with small modifications, such as the use of a longer capillary (at least 60 cm to the detection window instead of 30 cm since short capillary lengths are not practical with the LS40 detector), a higher CE voltage (30 kV), and the presence of 1 mM BrNS in the BGE. At first, only a partial resolution of MTX enantiomers was obtained. Therefore, various parameters such as CD concentration, methanol (MeOH) percentage, and capillary length were studied in order to improve the chiral separation. These aspects were optimized as separate parameters.

The influence of the concentration of HP-β-CD on the enantioseparation of MTX was investigated in the range from 1 to 10 mg/mL because the degree of complexation of the enantiomers is affected by the concentration of the chiral selector. The resolution gradually deteriorated when the concentration increased up to 10 mg/mL. In addition, an increase in the CD concentration resulted in shorter migration times. Because of the lower electrophoretic mobility of the inclusion MTX/HP-β-CD complexes in comparison with the free analyte, the complexes migrate closer to the EOF. Eventually, 3 mg/mL of HP-β-CD was chosen for further experiments as a compromise between resolution and analysis time. Interestingly, the peak areas observed with quenched phosphorescence detection were hardly affected by the HP-β-CD concentration, indicating that free and complexed MTX have similar quenching properties toward BrNS.

Since the CD concentration could not improve the separation further, the addition of different percentages of MeOH (10%, 20%, and 25%) was studied. Adding organic modifier to the running buffer may affect the enantiomeric resolution, as well as other parameters such as the EOF, the conductivity of the BGE, and the analysis time. With higher percentages of MeOH, the chiral resolution improved, but this added to the analysis time. Twenty percent MeOH was chosen as a trade-off between both parameters. However, the enantioseparation of MTX was still only partial. We hypothesized that the 6-mm detection window of the lamp-based phosphorescence detector could contribute to the overall band broadening. The detection window was reduced in size by means of black shrink tubing around the capillary. Figure [3](#Fig3){ref-type="fig"} shows the electropherograms obtained for a solution of 5 × 10^−6^ M [l-]{.smallcaps}MTX and 2.5 × 10^−6^ M [d]{.smallcaps}-MTX using different detection window lengths. Reducing the window to about 2 mm improved the resolution, but with even narrower detection windows, a significant loss of signal (*I*~0~/*I*) was observed. As a compromise, the 2-mm window was chosen for further experiments. The capillary length was increased (from 60 to 70 cm) to further improve the separation. Finally, in order to find the optimal BrNS concentration and obtain the highest phosphorescence intensity, it was varied from 0.5 to 1.5 mM, but no major differences were observed. Since the use of 1 mM BrNS resulted in a slightly higher phosphorescence intensity, it was chosen as the best BrNS concentration (data not shown). Fig. 3EKC phosphorescence: influence of the detection window length on the phosphorescence intensity and chiral resolution of [d,l]{.smallcaps}-MTX. Sample, 5 × 10^−6^ M [l]{.smallcaps}-MTX + 2.5 × 10^−6^ M [d]{.smallcaps}-MTX; BGE, 1 mM BrNS with 3 mg/mL HP-β-CD and 20% MeOH in 25 mM phosphate (pH 7.0); untreated fused-silica capillary, 110 cm (60 cm to the detector window) × 75-μm i.d. Other conditions are described in the experimental section. The BGE was purged with nitrogen to remove oxygen. The electropherograms are vertically shifted for clarity

In summary, the chiral separation of MTX enantiomers with quenched phosphorescence detection was achieved using as BGE 1 mM BrNS with 3 mg/mL HP-β-CD and 20% MeOH in 25 mM phosphate buffer (pH 7.0) in a capillary of 70 cm to the detector (with a detection window of about 2 mm). These conditions allowed the separation of MTX with a resolution of \~1.5. Finally, the LOD and LOQ were calculated from the S/N ratio equal to 3 and 10, respectively, when injecting a solution of 2.5 × 10^−6^ M [l-]{.smallcaps}MTX and 1.25 × 10^−6^ M [d]{.smallcaps}-MTX. A LOD of 3.2 × 10^−7^ M and a LOQ of 1.1 × 10^−6^ M were achieved for both enantiomers. This is a major improvement compared with the LODs reported in the literature for the chiral separation of MTX with UV absorption detection: 4 × 10^−6^ M for CE \[[@CR38]\], 1.5 × 10^−6^ M for MECK \[[@CR5]\], and 2 × 10^−6^ M for HPLC \[[@CR6]\].

Application to formulations and biological samples {#Sec9}
--------------------------------------------------

The developed method was applied to determine the optical purity of standards and a pharmaceutical formulation of [l-]{.smallcaps}MTX. The level of [d]{.smallcaps}-MTX in both samples was quantified by means of the standard addition method. The percentages of spiked [d]{.smallcaps}-MTX ranged from 0% to 3% (*w*/*w*), relative to a nominal concentration of **[l-]{.smallcaps}**MTX of 10^−4^ M. The actual level of the [l]{.smallcaps}**[-]{.smallcaps}**enantiomer was too high to be determined immediately (upper limit of the calibration range is 1 × 10^−5^ M) and was therefore verified separately after dilution.

In a quenching experiment, the peak heights do not increase linearly with the analyte concentration. Linear calibration curves were obtained by plotting *I*~0~/*I*, according to the Stern--Volmer equation (Eq. [1](#Equ1){ref-type=""}), versus the percentage of [d]{.smallcaps}-MTX (X) added to the sample. The equations obtained, by means of a linear regression analysis, were: *y* = 0.228*x* + 1.248 (*r*^2^ = 0.9994) for the standard and *y* = 0.249*x* + 1.148 (*r*^2^ = 0.9899) for the pharmaceutical formulation. Figure [4](#Fig4){ref-type="fig"} shows the electropherograms obtained for both samples when 0% [d]{.smallcaps}-MTX was added. Percentages of 1.1% (chemical standard) and 0.6% [d]{.smallcaps}-MTX (pharmaceutical formulation) were calculated by solving the above equations for *y* = 1. Fig. 4[d]{.smallcaps}-MTX impurity determination in a standard sample (*top*) and in a pharmaceutical formulation (*bottom*); unspiked samples with a nominal L-MTX concentration of 1 × 10^−4^ M. Untreated fused silica capillary, 120 cm (70 cm to the detector window) × 75-μm i.d. Other conditions as in Fig. [3](#Fig3){ref-type="fig"}. The electropherograms are vertically shifted for clarity

A short-term degradation study was also carried out to investigate the possible racemization of [l-]{.smallcaps}MTX. Nine standard samples of 10^−4^ M **[l-]{.smallcaps}**MTX were stored at 4, 20, and 37 °C and analyzed after 2, 6, and 24 h. The [d]{.smallcaps}-MTX levels were very similar in all samples (the ratios *I*~0~/*I* ranged from 1.30 to 1.36), which showed that no significant racemization of [l-]{.smallcaps}MTX occurred under the conditions studied.

Finally, as a proof-of-principle experiment for the application of the developed method to biological samples, [l-]{.smallcaps}MTX was determined in a cell culture extract from human CEM leukemia cells. The extract was spiked with 1 μM [l-]{.smallcaps}MTX, a realistic level in pharmacokinetic and pharmacodynamic experiments. As demonstrated in Fig. [5](#Fig5){ref-type="fig"}, the intracellular components caused little interference in the quenched phosphorescence detection of [l-]{.smallcaps}MTX. The [l-]{.smallcaps}MTX peak was above the LOD level of 3.1 × 10^−7^ M (based on the noise level measured over the range 5--10 min), but for proper quantitation, slightly higher levels or sample preconcentration would be preferred. The developed method will be useful for determining the intracellular concentration of MTX and can be applied in future studies on the dynamic equilibrium between influx and efflux routes. Fig. 5EKC phosphorescence of [l]{.smallcaps}-MTX (1 μM) in a cell culture extract. Experimental conditions as in Fig. [4](#Fig4){ref-type="fig"}

Concluding remarks {#Sec10}
==================

Following the batch study of the phosphorescence characteristics of MTX (direct and indirect phosphorescence), the quenched phosphorescence mode was chosen as the detection method for the chiral separation of MTX enantiomers by EKC. Under the optimized conditions, 1 mM BrNS with 3 mg/mL HP-β-CD and 20% MeOH in 25 mM phosphate buffer (pH 7.0), the enantiomeric separation of [l-]{.smallcaps} and [d]{.smallcaps}-MTX was obtained with a resolution \~1.5. Under these conditions, a LOD of 3.2 × 10^−7^ M was achieved for both enantiomers, improving the LODs previously reported in the literature with about an order of magnitude. Finally, the developed method was satisfactorily applied to the enantiomeric purity control of standards and a pharmaceutical formulation. A short-term stability study did not show any major degree of racemization in aqueous solution up to 24 h, not even at 37 °C. The method was also found to be suitable for studying MTX in cell culture extracts.
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